ALDEYRA THERAPEUTICS, INC. (ALDX) Free cash flow 2016–2023
ALDEYRA THERAPEUTICS, INC. (ALDX) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$30.3MFY2023 · since FY2016: -$15.2M → -$30.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2023 | -$30.3M | +46.5% |
| FY2022 | -$56.7M | -33.1% |
| FY2021 | -$42.6M | — |
| FY2019 | -$45.0M | -49.4% |
| FY2018 | -$30.1M | -56.5% |
| FY2017 | -$19.2M | -27.0% |
| FY2016 | -$15.2M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More ALDX financial trends
ALDX RevenueALDX Net incomeALDX Net marginALDX Gross profitALDX Gross marginALDX Operating incomeALDX Operating marginALDX Operating cash flowALDX Capital expendituresALDX Return on equityALDX Stock buybacksALDX Dividends paidALDX Total assetsALDX Total liabilitiesALDX Shareholders’ equityALDX overview →